

Filed: June 7, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

TEVA PHARMACEUTICALS USA, INC.,  
Petitioner,

v.

INDIVIOR UK LIMITED,  
Patent Owner.

---

Case IPR2016-00280  
Patent 8,475,832

---

**PETITIONER'S SECOND UPDATED MANDATORY NOTICES**

Teva Pharmaceuticals USA, Inc. (“Petitioner”) hereby updates its Mandatory Notices to inform the Board of a change in status in a Related Proceeding. Accordingly, pursuant to 37 C.F.R. § 42.8, Petitioner hereby provides the following updated Mandatory Notices.

**I. 37 C.F.R. § 42.8(b)(1) – REAL PARTY-IN-INTEREST (UNCHANGED)**

The real party-in-interest is Teva Pharmaceuticals USA, Inc., (“Teva” or “Petitioner”)<sup>1</sup>.

**II. 37 C.F. R. § 42.8(b)(2) – RELATED PROCEEDINGS (REVISED)**

The following proceedings may affect or be affected by a decision in this proceeding:

Name	Number	District
Indivior Inc. et al v. Sandoz Inc.	1-15-cv-01051	DED
Indivior Inc. et al v. Mylan Technologies Inc. et al	1-15-cv-00209	WVND

---

<sup>1</sup> Teva is an indirect, wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. Teva is owned by 1) Orvet UK, which in turn is owned by Teva Pharmaceuticals Europe B.V., which in turn is owned by Teva Pharmaceutical Industries Ltd. and 2) Teva Pharmaceutical Holdings Cooperative U.A., which in turn is owned by IVAX LLC, which is owned by Teva Pharmaceuticals USA, Inc.

Indivior Inc. et al v. Mylan Technologies Inc. et al	1-15-cv-01016	DED
Reckitt Benckiser Pharmaceuticals Inc. et al v. Alvogen Pine Brook, Inc.	1-15-cv-00477	DED
Reckitt Benckiser Pharmaceuticals Inc. et al. v. Teva Pharmaceuticals USA, Inc.	1-14-cv-01451	DED
Reckitt Benckiser Pharmaceuticals Inc. et al v. Par Pharmaceutical, Inc. et al	1-14-cv-00422	DED
Reckitt Benckiser Pharmaceuticals Inc. et al v. Alvogen Pine Brook Inc.	1-13-cv-02003	DED
Reckitt Benckiser Pharmaceuticals Inc. et al v. Watson Laboratories Inc., et al.	1-13-cv-01674	DED
Reckitt Benckiser Pharmaceuticals, Inc. et al v. Par Pharmaceutical, Inc. et al	1-13-cv-01461	DED

On June 3, 2006, the District Court for the District of Delaware in *Reckitt Benckiser Pharmaceuticals Inc., et al v. Par Pharmaceutical, Inc., et al*, 1-14-cv-00422, and *Reckitt Benckiser Pharmaceuticals Inc. et al v. Watson Laboratories Inc., et al.*, 1-13-01674, found that claims 1, 3, 6, and 15-19 of the

'832 patent are invalid as obvious over the prior art. The decision is filed on the docket for case 13-cv-01674.

The following administrative proceedings may affect or be affected by a decision in this proceeding:

Petitioner is aware of at least one currently-pending U.S. patent application that claims the benefit of the '514 Patent: U.S. Patent Application Serial No. 14/572,173 filed on December 16, 2014, which is pending.

**III. 37 C.F.R. § 42.8(b)(3) - LEAD AND BACKUP COUNSEL  
(UNCHANGED)**

Lead Counsel	Backup Counsel
Elizabeth Holland (Reg. No. 47, 657) GOODWIN PROCTER LLP The New York Times Building 620 Eight Avenue New York, NY 10018 Tel.: (212) 813-8800 Fax: (212) 355-3333 eholland@goodwinprocter.com	Jennifer A. Albert (Reg. No. 32,012) Eleanor M. Yost (Reg. No. 58,013) J. Coy Stull (Reg. No. 62,599) GOODWIN PROCTER LLP 901 New York Avenue NW Washington, DC 20001 Tel.: (202) 346-4000 Fax: (202) 346-4444 JAlbert@goodwinprocter.com eyost@goodwinprocter.com jstull@goodwinprocter.com  Elaine H. Blais Robert Frederickson III (both to seek <i>pro hac vice</i> admission) GOODWIN PROCTER LLP Exchange Place 53 State Street

	<p>Boston, Massachusetts 02109 Tel.: (617) 570-1000 Fax: (617) 523-1231 eblais@goodwinprocter.com rfrederickson@goodwinprocter.com</p> <p>Robert V. Cerwinski (to seek <i>pro hac vice</i> admission) GOODWIN PROCTER LLP The New York Times Building 620 Eighth Avenue New York, NY 10018 Tel.: (212) 813-8800 Fax: (212) 355-3333 rcerwinski@goodwinprocter.com</p>
--	---

**IV. 37 C.F.R. § 42.8(b)(4) - SERVICE INFORMATION (UNCHANGED)**

Please direct all correspondence to counsel at the contact information above.

Petitioner consents to service by electronic mail.

Dated: June 7, 2016

Respectfully submitted,

/Elizabeth J. Holland/

Elizabeth J. Holland

(Reg. No. 47,657)

*Counsel for Petitioner Teva Pharmaceuticals  
USA, Inc.*

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.